AstraZeneca Shares Seen Slipping 3% After Bristol Myers Merger Talks Reported
BMY sits 54% above its 52-week low of $42.52.
Summary
AstraZeneca shares are expected to drop up to 3% on Monday after reports of preliminary merger talks with Bristol Myers Squibb, following a Benzinga report that the two were in advanced talks to create a $400 billion pharma giant. The market reaction suggests skepticism about the deal's benefits for AstraZeneca, or concerns about execution risk. For Bristol Myers, which just posted a massive Q2 beat and raised guidance, a merger of this scale would be transformative but also introduce significant integration challenges. The talks are described as preliminary, so the outcome is highly uncertain.
At the time of this announcement, BMY was trading at $65.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $133.4B. The 52-week trading range was $42.52 to $65.66. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.